Jubilant Ingrevia commissions new cGMP facility for supplying Niacinamide to global clients
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
The order, part of an international framework agreement is to be executed between February to April, 2025
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
For people with relapsed or refractory diffuse large B-cell lymphoma
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The inspection conducted by EDQM at its Visakhapatnam facility
Subscribe To Our Newsletter & Stay Updated